Global (United States, European Union and China) Immune Checkpoint Agents Market Research Report 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Immune Checkpoint Agents Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Anti-PD-L1 Drug
  • 1.3.3 Anti-PD-1 Drug
  • 1.3.4 CTLA4
• 1.4 Market Segment by Application
  • 1.4.1 Global Immune Checkpoint Agents Market Share by Application (2019-2025)
  • 1.4.2 Lung Cancer
  • 1.4.3 Colorectal Cancer
  • 1.4.4 Breast Cancer
  • 1.4.5 Prostate Cancer
  • 1.4.6 Melanoma
  • 1.4.7 Blood Cancers
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Immune Checkpoint Agents Market Size
  • 2.1.1 Global Immune Checkpoint Agents Revenue 2014-2025
  • 2.1.2 Global Immune Checkpoint Agents Sales 2014-2025
• 2.2 Immune Checkpoint Agents Growth Rate by Regions
  • 2.2.1 Global Immune Checkpoint Agents Sales by Regions 2014-2019
  • 2.2.2 Global Immune Checkpoint Agents Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Immune Checkpoint Agents Sales by Manufacturers
  • 3.1.1 Immune Checkpoint Agents Sales by Manufacturers 2014-2019
  • 3.1.2 Immune Checkpoint Agents Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Immune Checkpoint Agents Revenue by Manufacturers (2014-2019)
  • 3.2.2 Immune Checkpoint Agents Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Immune Checkpoint Agents Market Concentration Ratio (CR5 and HHI)
• 3.3 Immune Checkpoint Agents Price by Manufacturers
• 3.4 Key Manufacturers Immune Checkpoint Agents Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Immune Checkpoint Agents Market
• 3.6 Key Manufacturers Immune Checkpoint Agents Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Anti-PD-L1 Drug Sales and Revenue (2014-2019)
  • 4.1.2 Anti-PD-1 Drug Sales and Revenue (2014-2019)
  • 4.1.3 CTLA4 Sales and Revenue (2014-2019)
• 4.2 Global Immune Checkpoint Agents Sales Market Share by Type
• 4.3 Global Immune Checkpoint Agents Revenue Market Share by Type
• 4.4 Immune Checkpoint Agents Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Immune Checkpoint Agents Sales by Application

6 United States

• 6.1 United States Immune Checkpoint Agents Breakdown Data by Company
• 6.2 United States Immune Checkpoint Agents Breakdown Data by Type
• 6.3 United States Immune Checkpoint Agents Breakdown Data by Application

7 European Union

• 7.1 European Union Immune Checkpoint Agents Breakdown Data by Company
• 7.2 European Union Immune Checkpoint Agents Breakdown Data by Type
• 7.3 European Union Immune Checkpoint Agents Breakdown Data by Application

8 China

• 8.1 China Immune Checkpoint Agents Breakdown Data by Company
• 8.2 China Immune Checkpoint Agents Breakdown Data by Type
• 8.3 China Immune Checkpoint Agents Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Immune Checkpoint Agents Breakdown Data by Company
• 9.2 Rest of World Immune Checkpoint Agents Breakdown Data by Type
• 9.3 Rest of World Immune Checkpoint Agents Breakdown Data by Application
• 9.4 Rest of World Immune Checkpoint Agents Breakdown Data by Countries
  • 9.4.1 Rest of World Immune Checkpoint Agents Sales by Countries
  • 9.4.2 Rest of World Immune Checkpoint Agents Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Bristol Myers Squibb
  • 10.1.1 Bristol Myers Squibb Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Immune Checkpoint Agents
  • 10.1.4 Immune Checkpoint Agents Product Introduction
  • 10.1.5 Bristol Myers Squibb Recent Development
• 10.2 Merck
  • 10.2.1 Merck Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Immune Checkpoint Agents
  • 10.2.4 Immune Checkpoint Agents Product Introduction
  • 10.2.5 Merck Recent Development
• 10.3 AstraZeneca
  • 10.3.1 AstraZeneca Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Immune Checkpoint Agents
  • 10.3.4 Immune Checkpoint Agents Product Introduction
  • 10.3.5 AstraZeneca Recent Development
• 10.4 Roche
  • 10.4.1 Roche Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Immune Checkpoint Agents
  • 10.4.4 Immune Checkpoint Agents Product Introduction
  • 10.4.5 Roche Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Immune Checkpoint Agents Sales Channels
  • 11.2.2 Immune Checkpoint Agents Distributors
• 11.3 Immune Checkpoint Agents Customers

12 Market Forecast

• 12.1 Global Immune Checkpoint Agents Sales and Revenue Forecast 2019-2025
• 12.2 Global Immune Checkpoint Agents Sales Forecast by Type
• 12.3 Global Immune Checkpoint Agents Sales Forecast by Application
• 12.4 Immune Checkpoint Agents Forecast by Regions
  • 12.4.1 Global Immune Checkpoint Agents Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Immune Checkpoint Agents Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details